<![CDATA[FDA Approves PGDx Elio Tissue Complete CDx for Advanced Melanoma]]>

RegulatoryapprovedPGDx elio tissue complete CDxPositive

AI Analysis

Summary

The FDA approved PGDx elio tissue complete CDx, a companion diagnostic test that identifies advanced melanoma patients with BRAF V600E/K variants eligible for targeted therapy treatment.

Outcome Details

FDA approved PGDx elio tissue complete CDx companion diagnostic for identifying advanced melanoma patients with BRAF V600E/K variants eligible for targeted therapy

Importance:7/10

Sentiment:

0.85

FDA approvalcompanion diagnosticmelanomaBRAF V600E/Koncology

Read the original article

Published by Cancer Network on August 11, 2026 10:00 PM

Read Original